1877 — Shanghai Junshi Biosciences Co Income Statement
0.000.00%
- HK$21.46bn
- HK$21.92bn
- CNY1.95bn
Annual income statement for Shanghai Junshi Biosciences Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,595 | 4,025 | 1,453 | 1,503 | 1,948 |
Cost of Revenue | |||||
Gross Profit | 1,218 | 2,767 | 927 | 868 | 1,425 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,251 | 4,583 | 4,119 | 3,960 | 3,287 |
Operating Profit | -1,656 | -558 | -2,666 | -2,457 | -1,339 |
Gain / Loss on Sale of Assets | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,672 | -595 | -2,677 | -2,492 | -1,358 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,669 | -731 | -2,584 | -2,536 | -1,380 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1,669 | -721 | -2,388 | -2,283 | -1,281 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,669 | -721 | -2,388 | -2,283 | -1,281 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.03 | -0.811 | -2.64 | -2.43 | -1.31 |
Dividends per Share |